• Chugai and Lilly Enter into a License Agreement for Oral GLP-1 Agonist

    • September 28, 2018
    • Posted By : admin
    • 0 Comment
    •   149 views

    Chugai Pharmaceutical Co., Ltd. and Eli Lilly and Company announced they have entered into a license agreement for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist. OWL833 is a Phase 1-ready asset that is being studied for the treatment of type 2 diabetes.

    “As a global leader in diabetes care, Lilly is committed to developing the next generation of diabetes therapies”

    Under the terms of the agreement, Lilly will receive worldwide development and commercialization rights to OWL833. Chugai will receive an upfront payment of $50 million and is eligible for milestone payments based on achievement of certain predetermined milestones. If the molecule is successfully commercialized, Chugai would also be eligible for royalty payments.

    “As a global leader in diabetes care, Lilly is committed to developing the next generation of diabetes therapies,” said Daniel Skovronsky, M.D., Ph.D., Lilly’s Chief Scientific Officer and President of Lilly Research Laboratories. “This exciting new opportunity from Chugai could represent a significant step forward for improving outcomes for people with diabetes.”

    “We are very pleased to announce the license agreement of OWL833 with Lilly, a world-leading company in diabetes care,” said Yasushi Ito, M.D., Ph.D., Chugai’s Executive Vice President, Co-head of Project & Lifecycle Management Unit. “We believe OWL833 can be a best-in-class oral non-peptide GLP-1 receptor agonist and that its value will be further enhanced through Lilly’s clinical development to contribute to people around the world who live with diabetes.”

    There will be no change to Chugai’s consolidated financials forecast for the fiscal year ending December 2018 as a result of this transaction.

    This transaction will be reflected in Lilly’s reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP). There will be no change to Lilly’s 2018 non-GAAP earnings per share guidance as a result of this transaction.

    This transaction is subject to potential competition authority clearances and other customary closing conditions.

  149 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!